2 withdrawn. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Withdrawn 2 |
Follow Phobic Disorders: new trials by email Literature Review of Phobic Disorders trials Research Report on Phobic Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CHI-902 for Treatment of Social Anxiety Disorder CHI-902, Placebo - Social Anxiety Disorder | Phase 2 | Withdrawn | Canopy Growth Corporation | 2020-01-24 | 2020-06-04 | |
| D-Cycloserine and Virtual Reality Exposure Therapy Seromycin, Virtual Reality Exposure Therapy, Placebo - Social Anxiety Disorder | Phase 2 | Withdrawn | Georgia State University | 2015-01-01 | 2018-04-13 |
Phobia, Social (2) · Anxiety Disorders (1) · Marijuana Abuse (1)
Mental Disorders (2) · Anxiety Disorders (1) · Chemically-Induced Disorders (1) · Substance-Related Disorders (1)
Cycloserine (1) · Virtual Reality Exposure Therapy (1)
Canopy Growth Corporation (1) · Georgia State University (1)
Canada (1) · United States (1)
Mark Ware, MD (1) · Page Anderson, PhD (1)